Citations

Clear

3030 citation(s) found for "Susan, M".

ADHD Diagnosis and Treatment Guidelines: A Historical Perspective
Wolraich, Mark L., Chan, Eugenia, Froehlich, Tanya E. , Lynch, Rachel L., Bax, Ami , Redwine, Susan T., Ihyembe, Demvihin, Hagan, Joseph F.

Mayo Clinic

Pediatrics | September 30, 2019 | Volume: 144 | Issue: 4 | Pages: No page available

10.1542/peds.2019-1682 | PMID 31570649 Get It

Attention-deficit/hyperactivity disorder (ADHD) is the most common behavioral condition and the second most common chronic illness in children. The observance of specific behaviors in multiple settings have remained the most successful method for diagnosing the condition, and although there are differences in specific areas of the brain, and a high heritability estimate (∼76%), they are not diagnostically specific. Medications, and particularly stimulant medication, have undergone rigorous studies to document their efficacy dating back to the 1970s. Likewise, behavioral interventions in the form of parent training and classroom programs have demonstrated robust efficacy during the same time period. Both medication and behavioral interventions are symptomatic treatments. The availability of only symptomatic treatments places ADHD in the same category as other chronic conditions such as diabetes and asthma. Successful treatment of most individuals requires ongoing adherence to the therapy. Improved communication between patients and their families, primary and mental health providers, and school personnel is necessary for effective ADHD treatment. Further enhancement of electronic systems to facilitate family, school, and provider communication can improve monitoring of ADHD symptoms and functional performance. The American Academy of Pediatrics ADHD guidelines were initially developed to help primary care clinicians address the needs of their patients with ADHD and were further refined with the second revision in 2019.
A Simulator-Based Comparison of a Novel 3D and a Conventional 3D Vision System-Surgical Performance and Subjective Ratings
Svenner, Annika, Fan, Xuelong , Forsman, Mikael , Shabo, Ivan , Kjellman, Magnus , Hallbeck, M. Susan

Mayo Clinic

Inventions | September 27, 2019 | Volume: 4 | Issue: 4 | Pages: 58

10.3390/inventions4040058 Get It

In laparoscopy, novel three-dimensional laparoscopic vision systems (3D LVS) without glasses (3D−) have been invented. While standard 3D LVS with glasses (3D+) have shown advantages over original two-dimensional systems, quantitative comparisons of surgical performance between 3D− and 3D+ systems are still lacking. The aim is to compare the systems in simulated robotic surgery tasks. In a crossover study, 18 medical students performed four basic laparoscopic tasks in the validated Simball Box simulator with authentic surgical instruments by using the 3D+ and 3D− systems. Performance was measured by the number of errors and the task’s duration. Subjective ratings of perceptions and preference were assessed after each test. There were significant, but still minor, advantages for the conventional 3D+ system regarding spatial orientation and sense of depth. Overall, ten and eight subjects preferred 3D+ and 3D− systems, respectively. No significant differences were found in performance, post-operative physicals or eye symptoms. The novel 3D− system was similar to the conventional 3D+ system regarding performance and overall preference, while there were minor advantages for the 3D+ system in the subjective ratings. Since the 3D− system is a new invention, it should have a higher potential of usability improvements.
Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis
Link, Brian K. , Call, Timothy G. , Ansell, Stephen M. , Liebow, Mark , Xiang, Jinhua , Nowakowski, Grzegorz S. , Famà, Angelo , Link, Brian K , Larson, Melissa C. , Habermann, Thomas M. , Feldman, Andrew L. , Maurer, Matthew J. , Slager, Susan L. , Stapleton, Jack T. , Cerhan, James R.

Mayo Clinic

Clinical Infectious Diseases | September 20, 2019 | Volume: 71 | Issue: 5 | Pages: 1221-1228

10.1093/cid/ciz940 | PMID 31671178 Get It

AbstractBackgroundHuman pegivirus (HPgV) is a single-strand RNA virus belonging to the Flaviviridae. Although no definitive association between HPgV infection and disease has been identified, previous studies have suggested an association of HPgV viremia with risk of lymphomas.MethodsWe conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall and by geographic region and lymphoma subtype.ResultsThe overall OR for lymphoma was 2.85 (95% CI, 1.98–4.11), with statistically significantly elevated ORs observed in 8 of 15 studies. There was a small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot provided no evidence for publication bias. The strongest association with lymphoma risk was observed for studies from Southern Europe (OR, 5.68 [95% CI, 1.98–16.3]), whereas weaker ORs (with 95% CIs) were observed for studies from North America (2.24 [1.76–2.85]), Northern Europe (2.90 [.45–18.7), and the Middle East (2.51 [.87–7.27]), but all of similar magnitude. Participants with HPgV viremia had statistically significantly increased risks (OR [95% CI]) for developing diffuse large B-cell (3.29 [1.63–6.62]), follicular (3.01 [1.95–4.63]), marginal zone (1.90 [1.13–3.18]), and T-cell (2.11 [1.17–3.89]) lymphomas, while the risk for Hodgkin lymphoma (3.53 [.48–25.9]) and chronic lymphocytic leukemia (1.45 [.45–4.66]) were increased but did not achieve statistical significance.ConclusionsThis meta-analysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major lymphoma subtypes.
Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis
Lou, Susan , Watthanasuntorn, Kanramon , Cheungpasitporn, Wisit , Lukens, Frank , Pungpapong, Surakit , Ungprasert, Patompong , Lukens, Frank J., Cheungpasitporn, Wisit , Pungpapong, Surakit , Wijarnpreecha, Karn , Kröner, Paul T. , Keaveny, Andrew P.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | September 20, 2019 | Volume: 32 | Issue: 5 | Pages: 601-608

10.1097/meg.0000000000001541 | PMID 31567712 Get It

Objectives Recent studies have suggested that small intestinal bacterial overgrowth (SIBO) could be a predisposing factor for nonalcoholic fatty liver disease (NAFLD) although the results were inconsistent. This systematic review and meta-analysis was conducted with the aim to summarize all available data. Methods A comprehensive literature review was conducted utilizing MEDLINE and EMBASE databases through September 2018 to identify all studies that compared the risk of NAFLD among patients with SIBO versus those without SIBO. Effect estimates from each study were extracted and combined together using the random effect, generic inverse variance method of DerSimonian and Laird. Results A total of 10 studies with 1093 participants fulfilled the eligibility criteria and were included in the meta-analysis. A significant association between NAFLD and SIBO was observed with the pooled odds ratio of 3.82 (95% confidence interval, 1.93–7.59; I 2 65%). Funnel plot is relatively symmetric and is not suggestive of the presence of publication bias. Conclusion A significant association between NAFLD and SIBO was observed in this meta-analysis.
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, Robert B., Adib, Gemma, Adler, Robert A. , Alexander, Ivy M. , Amenta, Kelly C, Blank, Robert D. , Brox, W. Timothy , Carmody, Emily E., Chapman‐Novakofski, Karen , Cody, Kathleen, Cooper, Cyrus , Crandall, Carolyn , Dirschl, Douglas R. , Eagen, Thomas J. , Elderkin, Ann L, Fujita, Masaki , Greenspan, Susan L., Halbout, Philippe , Hochberg, Marc C. , Jeray, Kyle J. , Kearns, Ann E. , King, Toby, Koinis, Thomas F., Koontz, Jennifer Scott , Kužma, Martin , Lindsey, Carleen, Lorentzon, Mattias , Lyritis, George P., Michaud, Laura Boehnke, Miciano, Armando S., Mujahid, Nadia , Olenginski, Thomas P. , Puzas, J. Edward, Rizou, Stavroula , Thompson, Elizabeth , Tosi, Laura L. , Tracer, Howard, Clarke, Bart L , Cooper, Cyrus , Crandall, Carolyn J , Kužma, Martin , Morin, Suzanne N , Napoli, Nicola , Khosla, Sundeep , Lorentzon, Mattias , Åkesson, Kristina , Clarke, B.L. , Javaid, M K , Rosen, Clifford J. , Saag, Kenneth G. , Khosla, Sundeep , Kiel, Douglas P.

Mayo Clinic

Journal of Bone and Mineral Research | September 20, 2019 | Volume: 35 | Issue: 1 | Pages: 36-52

10.1002/jbmr.3877 | PMID 31538675 Get It

ABSTRACT Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fracture among people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, and subcutaneous pharmacotherapies are efficacious and can reduce risk of future fracture. Patients need education, however, about the benefits and risks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first-line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive but may be beneficial for selected patients at high risk. Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the early post-fracture period, prompt treatment is recommended. Adequate dietary or supplemental vitamin D and calcium intake should be assured. Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects. Patients should be strongly encouraged to avoid tobacco, consume alcohol in moderation at most, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease). © 2019 American Society for Bone and Mineral Research.
Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial
Haque, Muhammad , Zhu, Hongjian , Rowan, Paul J. , Aisiku, Imoigele P. , Juneja, Harinder S., Alderman, Susan , Barreto, Andrew D. , Suárez, José I. , Bambhroliya, Arvind , Hasan, Khader M. , Kassam, Mallikarjuna Rao, Aronowski, Jaroslaw , Gee, Adrian P. , Cox, Charles S. , Grotta, James C. , Savitz, Sean I. , Vahidy, Farhaan S , Rahbar, Mohammad H. , Lee, Dean Anthony , Grotta, James C

Mayo Clinic

Stem Cells | September 17, 2019 | Volume: 37 | Issue: 11 | Pages: 1481-1491

10.1002/stem.3080 | PMID 31529663 Get It

AbstractCellular therapy is a promising investigational modality to enhance poststroke recovery. We conducted a single-arm, phase I clinical trial to determine the safety and feasibility of intravenous (IV) administration of autologous bone marrow mononuclear cells (MNCs) after acute ischemic stroke (AIS). Patients with moderate severity of AIS underwent bone marrow harvest followed by IV reinfusion of MNCs within 24–72 hours of onset. A target dose of 10 million cells per kilogram was chosen based on preclinical data. Patients were followed up daily during hospitalization and at 1, 3, 6, 12, and 24 months for incidence of adverse events using laboratory, clinical (12 months), and radiological (24 months) parameters. The trial was powered to detect severe adverse events (SAEs) with incidences of at least 10% and planned to enroll 30 patients. Primary outcomes were study-related SAEs and the proportion of patients successfully completing study intervention. A propensity score-based matched control group was used for the estimation of effect size (ES) for day-90 modified Rankin score (mRS). There were no study-related SAEs and, based on a futility analysis, enrolment was stopped after 25 patients. All patients successfully completed study intervention and most received the target dose. Secondary analysis estimated the ES to be a reduction of 1 point (95% confidence interval: 0.33–1.67) in median day-90 mRS for treated patients as compared with the matched control group. Bone marrow harvest and infusion of MNCs is safe and feasible in patients with AIS. The estimated ES is helpful in designing future randomized controlled trials. Stem Cells 2019;37:1481–1491
The Impact of a Multicomponent Integrative Intervention on Symptoms and Health Related Quality of Life for Patients with Pulmonary Hypertension
Visger, Tania Von , Dabbs, Annette DeVito , Thrane, Susan E. , Klatt, Maryanna , Chlan, Linda L. , Happ, Mary Beth

Mayo Clinic

B18. ENHANCING QUALITY OF LIFE AND DISEASE MANAGEMENT IN PULMONARY CONDITIONS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2643-A2643

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2643 Get It

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Lindström, Sara , Wang, Lu , Smith, Erin N. , Gordon, William, Vlieg, Astrid van Hylckama , Andrade, Mariza de , Brody, Jennifer A. , Pattee, Jack , Haessler, Jeffrey, Brumpton, Ben , Suchon, Pierre , Chen, Ming‐Huei , Germain, Marine , Wiggins, Kerri L. , Brækkan, Sigrid K. , Armasu, Sebastian M. , Jackson, Rebecca D., Giulianini, Franco, Puurunen, Marja , Ibrahim, Manal , Heckbert, Susan R. , Natarajan, Pradeep , Klarin, Derek , Program, The Million Veteran, Vries, Paul S. de , Sabater‐Lleal, Maria , Group, The CHARGE Hemostasis Working, Bammler, Theo K. , Frazer, Kelly A. , McCauley, Bryan M. , Pankow, James S. , Reiner, Alex P. , Gabrielsen, Maiken E. , Kim, Jihye , McKnight, Barbara, Hansen, J.-B., Heit, John A. , Tang, Weihong , Morange, Pierre‐Emmanuel , Johnson, Andrew D. , Kabrhel, Christopher , Trégouët, David‐Alexandre , Smith, Nicholas L. , Assimes, Themistocles L. , Ballantyne, Christie M. , Hansen, John‐Bjarne , Frazer, Kelly A , de Andrade, Mariza , Assimes, Themistocles L , Wiggins, Kerri L , Ballantyne, Christie M , Natarajan, Pradeep , Braekkan, Sigrid K , Germain, Marine , Brumpton, Ben , Sabater-Lleal, Maria , Pankow, James S , Tang, Weihong , Brody, Jennifer A , Chasman, Daniel I. , Turman, Constance , MacDonald, James W. , Pankratz, Nathan , Nielsen, Jonas Bille , Damrauer, Scott M , Program, The Million Veteran, Huffman, Jennifer E. , Group, The CHARGE Hemostasis Working, Taylor, Kent D. , Deleuze, Jean‐François , O'Donnell, Chris J., Kraft, Peter , Rosendaal, Frits R , Psaty, Bruce M. , Kooperberg, Charles , Hveem, Kristian , Ridker, Paul M.

Mayo Clinic

Blood | August 16, 2019 | Volume: 134 | Issue: 19 | Pages: 1645-1657

10.1182/blood.2019000435 | PMID 31420334 Get It

In this work related to familial aggregation of familial venous thromboembolism, the investigators report genomic and transcriptomic association of 16 novel susceptibility loci for venous thromboembolism.